(Q39725435)

14 September 2017

1 reference

title

Probucol: a review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia (English)

1 reference

14 September 2017

0 references

2

R N Brogden

1 reference

14 September 2017

R C Heel

1

1 reference

14 September 2017

T M Speight

series ordinal

3

1 reference

14 September 2017

G S Avery

series ordinal

4

1 reference

14 September 2017

publication date

1 June 1978

1 reference

14 September 2017

1 reference

14 September 2017

volume

15

1 reference

14 September 2017

issue

6

1 reference

14 September 2017

page(s)

409-428

1 reference

[Action of the new hypocholesteremic agent DH-581 (dithiobisphenol) in humans]

14 September 2017

cites work

1 reference

12 December 2020

Probucol: A new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia

1 reference

12 December 2020

Sensitization to epinephrine-induced ventricular fibrillation produced by probucol in dogs

1 reference

12 December 2020

The effect of [4,4′-(isopropylidenedithio)bis(2,6-di-t-butylphenol)] (DH-581) on serum lipids and lipoproteins in human subjects

1 reference

12 December 2020

Hypocholestece:rolesmic Effect of 4,4′-(Isopropylidenedithio)-Bis(2,6-di-t-Butylphenol) (Probucol)

1 reference

12 December 2020

Newer hypolipidemic agents

1 reference

12 December 2020

An overview of the biochemical pharmacology of probucol

1 reference

12 December 2020

Influence of 4,4'-(Isopropylidenedithio)bis(2,6-di-t-butylphenol) (DH-581) on Experimental Atherosclerosis in Rabbits

1 reference

12 December 2020

Effect of probucol in hyperlipidemic patients during two years of administration

1 reference

12 December 2020

Lipid Lowering Drugs and Coronary Heart Disease

1 reference

12 December 2020

Mode of action of a new hypocholesteraemic drug (DH-581) in familial hypercholesteraemia.

1 reference

12 December 2020

Long-Term Oral Administration of Probucol [4, 4‘-(Isopropylidenedithio) bis (2, 6-di-t-Butylphenol)] (DH-581) in the Management of Hypercholesterolemia*

1 reference

12 December 2020

Endocrine and metabolic indices during administration of a lipophilic bis‐phenol, probucol

1 reference

12 December 2020

Probucol in the long-term treatment of hypercholesterolaemia

1 reference

12 December 2020

Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid

1 reference

12 December 2020

Probucol, a new cholesterol lowering drug

1 reference

12 December 2020

The additive effect of probucol on diet in hyperlipidemia

1 reference

12 December 2020

Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemia

1 reference

12 December 2020

Toxicity of (4,4'-(isopropylidenedithio)bis(2,6-di-t-butylphenol)), probucol, in mice, rats, dogs and monkeys: demonstration of a species-specific phenomenon.

1 reference

12 December 2020

Biphenabid (Probucol): a new hypocholesterolemic agent

1 reference

12 December 2020

The additive effects of clofibrate and probucol (DH-581) on rat serum cholesterol

1 reference

12 December 2020

Treatment of severe and mild hypercholesterolaemia with probucol and neomycin.

1 reference

12 December 2020

Antiplatelet agents in coronary disease: are they of prophylactic value?

1 reference

12 December 2020

10.2165/00003495-197815060-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

14 September 2017

1002704624

0 references

1 reference